Evidence map›Paper›PMID 35838913›Full record

ArticlePituitary2022

A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery.

Elika Karvandi, John Gerrard Hanrahan, Danyal Zaman Khan, Pierre-Marc Boloux, Fion Bremner, Ivan Cabrilo, Neil Dorward, Joan Grieve, Sue Jackson, Glenda Jimenez and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elika KarvandiDepartment of Neurosurgery, University of Cambridge, Cambridge, UK. eek34@cam.ac.uk.
John Gerrard HanrahanDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Danyal Zaman KhanDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Pierre-Marc BolouxDepartment of Diabetes & Endocrinology, University College London Hospitals NHS Foundation Trust, London, UK.
Fion BremnerDepartment of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, London, UK.
Ivan CabriloDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Neil DorwardDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Joan GrieveDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Sue JacksonDepartment of Psychology, University of Plymouth, Plymouth, UK.
Glenda JimenezDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Inma SerranoDivision of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.
Victoria Anne NowakDepartment of Neuro-Ophthalmology, National Hospital for Neurology and Neurosurgery, London, UK.
Angelos KoliasDepartment of Neurosurgery, University of Cambridge, Cambridge, UK.
Stephanie E Baldeweg *Department of Diabetes & Endocrinology, University College London Hospitals NHS Foundation Trust, London, UK.
Hani Joseph Marcus *Division of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

purposePituitary adenomas affect patients' quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While clinical outcomes can assess treatment efficacy, they do not capture variations in QoL. We present the development and validation of a patient reported outcome measure (PROM) for patients with pituitary adenomas undergoing transsphenoidal surgery.

methodsThe COSMIN checklist informed the development of the pituitary outcome score (POS). Consecutive patients undergoing surgical treatment for suspected pituitary adenoma at a single centre were included prospectively. An expert focus group and patient interviews informed item generation. Item reduction was conducted through exploratory factor analysis and expert consensus, followed by assessment of the tool's validity, reliability, responsiveness, and interpretability.

results96 patients with a median age of 50 years validated the POS. The final questionnaire included 25 questions with four subscales: EQ-5D-5L-QoL, Visual Symptoms, Endocrine Symptoms and Nasal Symptoms.

conclusionThe POS is the first validated PROM for patients undergoing transsphenoidal surgery for a pituitary adenoma. This PROM could be integrated into contemporary practice to provide patient-centred outcomes assessment for this patient group, aligning more closely with patient objectives.

Indexed as

AdenomaPituitary NeoplasmsHumansMiddle AgedPatient Reported Outcome MeasuresQuality of LifeReproducibility of ResultsRetrospective StudiesTreatment OutcomePatient-reported outcome measurePituitary adenomaPituitary surgeryPROMQuality of lifeTranssphenoidal surgery

Identifiers

PMID35838913
PMCPMC9345822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.